Black Diamond Therapeutics develops MasterKey therapies that target genetically defined cancers, specifically non-small cell lung cancer and glioblastoma, by addressing multiple oncogenic mutations with a single treatment approach. This technology aims to overcome resistance mechanisms and reduce toxicities associated with wild-type proteins, enhancing treatment efficacy for a broader patient population.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current targeted cancer therapies often address a limited range of oncogenic mutations, leading to resistance and limiting the number of patients who can benefit. This narrow focus can result in treatment failure as cancer cells evolve and develop new mutations.
Solution
Black Diamond Therapeutics develops MasterKey therapies designed to target a broad range of genetically defined cancers, particularly non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Their approach aims to overcome resistance mechanisms by addressing multiple oncogenic mutations with a single therapeutic. By targeting a wider spectrum of mutations, MasterKey therapies intend to enhance treatment efficacy for a larger patient population while minimizing toxicities associated with wild-type proteins. The therapies are also designed to be brain-penetrant, enabling them to treat central nervous system (CNS) diseases.
Target Audience
The primary target audience includes patients living with genetically defined cancers, specifically non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and the physicians who treat them.
Features
- MasterKey therapies target multiple oncogenic mutations with a single treatment.
- Designed to overcome resistance mechanisms in cancer cells.
- Aims to minimize wild-type mediated toxicities.
- Focus on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
- Therapies are designed to be brain penetrant for treating CNS disease.